We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Direct Effect Media/Illumina

Events

27 Jul 2018 - 29 Jul 2018
25 Aug 2018 - 29 Aug 2018
29 Aug 2018 - 01 Sep 2018

Self-Expanding Heart Valve Treats Severe Aortic Stenosis

By HospiMedica International staff writers
Posted on 21 Mar 2018
Print article
Image: The Centera THV system (Photo courtesy of Edwards Lifesciences).
Image: The Centera THV system (Photo courtesy of Edwards Lifesciences).
A novel transcatheter heart valve (THV) valve aids treats patients with severe aortic stenosis requiring aortic valve replacement (AVR).

The Edwards Lifesciences (Irvine, CA, USA) Centera THV system is an ultra-low-profile self-expandable valve that consists of three treated bovine pericardial tissue leaflets attached to a nitinol frame and polyethylene terephthalate (PET) fabric. The stent frame is short, and therefore does not have a flared distal section that extends into the ascending aorta, facilitating centering and seating of the valve within the annulus. The shorter frame may also help to improve paravalvular sealing due to minimal protrusion of the valve frame into the left ventricle. Centera is available in 23 mm and 26 mm sizes.

The THV is provided with the valve pre-attached to the delivery system, facilitating rapid placement using a low-profile, 14F motorized delivery system that allows single-operator repositioning and retrieval. A dynamic expansion mechanism (DEM) allows transient sheath compression during valve delivery; immediately after it passes through, the DEM allows the sheath to return to its original low-profile diameter. Buttons control valve loading and deployment, while a handle release button and valve release mechanism permit the final release of the device.

“The Edwards Centera valve demonstrates extremely favorable early clinical safety and performance outcomes in the high surgical risk TAVR population,” said Didier Tchétché, MD, of Clinique Pasteur (Toulouse, France). “In addition to excellent patient outcomes, the valve also offers several unique features and an innovative tissue design, all of which simplify the procedure for clinicians.”

THV, sometimes called transcatheter aortic valve implantation (TAVI), may be an option for people who are considered at intermediate or high risk of complications from surgical aortic valve replacement. It can also be indicated in those who cannot undergo open-heart surgery.

Related Links:
Edwards Lifesciences

Print article
Radcal
FIME - Informa

Channels

Copyright © 2000-2018 Globetech Media. All rights reserved.